Can a narcolepsy drug fix ICU sleep problems?

NCT ID NCT07596342

Not yet recruiting Symptom relief Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a drug called gamma-hydroxybutyrate (GHB) can help intensive care patients get better deep sleep. Sleep problems are very common in the ICU and can lead to serious issues like confusion and longer recovery. The trial will give GHB or a placebo to 24 adults in the ICU and measure their sleep quality using brain wave recordings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gamma-hydroxybutyrate (GHB)
What this could lead to: If it works, this could provide a new way to improve restorative sleep in ICU patients, potentially reducing complications like delirium and difficulty weaning from ventilation.
What could go wrong: This is a small pilot study with only 24 participants, so results may not apply broadly. GHB can have side effects like dizziness or dependence, and its safety in critically ill patients is not fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CRITICAL CARE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sleep disorder sleep-wake disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CRITICAL CARE SLEEP DISORDER (DISORDER)

Contacts and locations

Locations

Intensive Care Unit, Hospital Pitié Salpêtrière

Paris, Île-de-France Region, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.